-
Company Insights
Innovation and Patenting activity of Rigel Pharmaceuticals Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Rigel Pharmaceuticals Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – R-835 in Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - R-835 in Lupus Erythematosus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. R-835 in Lupus Erythematosus Drug Details: R-835 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rademikibart in Asthma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rademikibart in Asthma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rademikibart in Asthma Drug Details: CBP-201 is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – R-835 in Rheumatoid Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - R-835 in Rheumatoid Arthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. R-835 in Rheumatoid Arthritis Drug Details: R-835 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Filgotinib Maleate in Axial Spondyloarthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Filgotinib Maleate in Axial Spondyloarthritis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Filgotinib Maleate in Axial Spondyloarthritis Drug Details: Filgotinib maleate (Jyseleca)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Fostamatinib Disodium in Hidradenitis Suppurativa
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fostamatinib Disodium in Hidradenitis Suppurativa report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Fostamatinib Disodium in Hidradenitis Suppurativa Drug Details: Fostamatinib disodium (Tavalisse, Tavlesse)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – R-289 in Inflammation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - R-289 in Inflammation report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. R-289 in Inflammation Drug Details: R-289 is under development for myelodysplastic syndrome and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Olutasidenib in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Olutasidenib in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Olutasidenib in Acute Myelocytic Leukemia (AML, Acute...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Olutasidenib in Myelodysplastic Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Olutasidenib in Myelodysplastic Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Olutasidenib in Myelodysplastic Syndrome Drug Details: Olutasidenib (Rezlidhia) is an isocitrate dehydrogenase-1...
-
Product Insights
Hepatobiliary System Tumor – Drugs In Development, 2023
Global Markets Direct’s, ‘Hepatobiliary System Tumor - Drugs In Development, 2023’, provides an overview of the Hepatobiliary System Tumor pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hepatobiliary System Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...